Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation

Published:2017-10-26 Issue:4 Volume:179 Page:598-605
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chen Yuhong¹,Cheng Yifei¹,Suo Pan¹,Yan Chenhua¹,Wang Yu¹,Chen Yao¹,Han Wei¹,Xu Lanping¹,Zhang Xiaohui¹^ORCID,Liu Kaiyan¹,Chang Lungji²,Xiao Lei³,Huang Xiaojun¹^ORCID

Affiliation:

1. Peking University People's Hospital; Peking University Institute of Haematology; Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation; Collaborative Innovation Centre of Haematology; Peking University; Beijing China

2. Shenzhen Geno-Immune Medical Institute; Beijing China

3. Innovative Cellular Therapeutics Co. Ltd; Beijing China

Funder

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14923/fullpdf

Reference30 articles.

1. Toxicities of chimeric antigen receptor T cells: recognition and management;Brudno;Blood,2016

2. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remission of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease;Brudno;Journal of Clinical Oncology,2016

3. [The efficacy and safety of second allogeneic hematopoietic stem cell transplantation for post-transplant hematologic malignancies relapse];Chen;Zhonghua Nei Ke Za Zhi,2011

4. Chimeric antigen receptors T cells as second line therapy for acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: high remission rate without causing graft versus host disease;Chen;Chinese Journal of Organ Transplantation,2016

5. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect;Cruz;Haematologica,2015

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adoptive cellular therapy after hematopoietic stem cell transplantation;American Journal of Hematology;2024-01-25

2. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity;Journal for ImmunoTherapy of Cancer;2024-01

3. Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies;Advanced Science;2023-10-31

4. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion;Human Cell;2023-07-07

5. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant;Frontiers in Immunology;2023-07-04